CD4 and tuberculosis: Of note, in Temprano, the trial who assessed in parallel the efficacy of early ART and IPT, IPT also reduced the risk tuberculosis by 66 % overall, 68 % in patients who had less than 500 CD4/mm3 at baseline and 63 % in those who had more than 500 CD4/mm3 at baseline.